Thursday, April 28, 2011
May 1st - Sporting Life's 10K Run
On May 1, Theralase will be in the finish area for Sporting Life's 10K run in support of kids with cancer and kids affected by childhood cancer by providing free laser therapy for your post-race aches and pains http://bit.ly/m3P4el
Monday, April 25, 2011
Cold Laser Therapy: Theory and Clinical Applications Seminar
Presented by Canadian Memorial Chiropractic College Division of Continuing Education and TheraLase Technologies Inc
Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)
Location:
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)
Location:
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
- Understand how laser light affects tissues and healing
- Identify musculoskeletal injury types that are indicated for primary or adjunctive laser treatment
- Design clinical laser treatment programs, including frequency of treatments, duration of care, and targeting for musculoskeletal injuries
- Select optimal laser dosage, including power and time settings, to treat a variety of musculoskeletal conditions in a clinical setting.
- Operate a laser safely, including treatment room design and patient and technician procedures
- Differentiate laser equipment through the comparison of key technology parameters
Thursday, April 21, 2011
Theralase Expands US Sales Force and Appoints Director of Investor Relations
Company adds experienced staff to build the revenue stream and improve shareholder value
April 21, 2011 (Marketwire Canada) --
TORONTO, ONTARIO -- Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that effective immediately, Mr. Brad Green, Ms. Kim Hillman, Mr. Derek McDonald and Mr. Cliff Majni have been appointed as Territory Sales Managers - Therapeutic Division, reporting to Scott Bleue, National Sales Manager. As well, Mr. Greg Bewsh has been appointed as Director of Investor Relations reporting to Roger Dumoulin-White, President and CEO.
Brad Green will be representing Theralase in the Southeast United States. He has over 20 years of experience in the medical device industry with 14 years as a sales professional which includes 5 years in a managerial role. He has sold to hospitals, physician offices, veterinary facilities and acute care centers.
Kim Hillman will be representing Theralase in the Western United States. She has 2 years direct experience in therapeutic laser sales and over 8 years in the pharmaceutical industry. Throughout this time, Kim has developed key relationships with thought leaders in the medical community across the Western United States.
Derek McDonald will be representing Theralase in Ontario. He has over 23 years experience in sales, with 13 years in medical laser sales.
Cliff Majni will be representing Theralase in the Midwest United States. He has over 15 years of sales experience in the pharmaceutical and medical equipment industries.
Greg Bewsh will be the new Director of Investor Relations for Theralase. He has more than 20 years experience in investor relations and financial services. He has advised clients with respect to strategic investor relations, corporate disclosure, governance, regulatory issues, raising capital, social media, and liquidity enhancement. Previously, Greg acquired extensive experience as Director of Investor Relations and Corporate Communications at two TSX and NASDAQ listed companies.
Roger Dumoulin-White, President & CEO of Theralase Technologies Inc., stated “I am excited by the quality of the new hires to our team, coming to us with significant experience in their respective fields. The improving US economy and the public’s desire for high efficacy, drug-free treatments in an aging population, is creating a significant opportunity for Theralase in 2011 and beyond. These new additions will support this vision.”
Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications in the United States, Canada and internationally. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Theralase Technologies Inc.
Roger Dumoulin - White, Greg Bewsh
President & CEO Director of Investor Relations
416-447-8455 ext. 225 416-447-8455 ext. 262
Wednesday, April 20, 2011
The Benefits of Laser Therapy
- Non-Toxic
- Non-Invasive
- Easy to Apply
- No Side Effects or Pain
- Extremely Safe
- Cost Effective for Practitioner and Patient
- Highly Effective for Patient (>90% efficacy)
- Growing Acceptance of Laser Technology
- Superior Alternative to: Analgesics, NSAID’s, Other Medications, Other Modalities
- Reduces Need for Surgery
- Virtually No Contra-Indications
Rapid Cell Growth – Laser light accelerates cellular reproduction and growth.
Faster Wound Healing – Laser light stimulates fibroblast development and accelerates collagen synthesis in damaged tissue.
Increased Metabolic Activity – Higher outputs of specific enzymes, greater oxygen and food particle loads for blood cells and thus greater production of the basic food source for cells, Adenosine Tri-Phosphate (ATP).
Reduced Fibrous Tissue Formation – Laser light reduces the formation of scar tissue following tissue damage from: cuts, scratches, burns or post surgery.
Anti-Inflammatory Action – Laser light reduces swelling caused by bruising or inflammation of joints to give enhanced joint mobility.
Increased Vascular Activity – Laser light induces temporary vasodilation increasing blood flow to damaged areas.
Stimulated Nerve Function – Slow recovery of nerve function in damaged tissue can result in “dead” limbs or numb areas. Laser light speeds the process of nerve cell reconnection to bring the numb areas back to life.
Tuesday, April 19, 2011
Tuesday, April 12, 2011
Cold Laser Therapy: Theory and Clinical Applications
Presented by Canadian Memorial Chiropractic College Division of Continuing Education and TheraLase Technologies Inc
Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)
Location:
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)
Location:
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
- Understand how laser light affects tissues and healing
- Identify musculoskeletal injury types that are indicated for primary or adjunctive laser treatment
- Design clinical laser treatment programs, including frequency of treatments, duration of care, and targeting for musculoskeletal injuries
- Select optimal laser dosage, including power and time settings, to treat a variety of musculoskeletal conditions in a clinical setting.
- Operate a laser safely, including treatment room design and patient and technician procedures
- Differentiate laser equipment through the comparison of key technology parameters
Friday, April 8, 2011
Theralase Receives Popular Mechanics Magazine "2010 Breakthrough Award" for the Company's Innovative Cancer Therapy Technology
Theralase Technologies Inc. (TSX VENTURE:TLT) has been awarded a 2010 Breakthrough Award by Popular Mechanics Magazine for its work with lasers in the destruction of cancer cells.
Theralase Technologies Inc. President and CEO, Roger Dumoulin-White joins Karen Brewer and Brenda Winkel of Virginia Tech to receive the award at the Hearst Tower in New York on October 5, 2010. Popular Mechanics Magazine's "Breakthrough Awards" is honouring the year's most impressive advances in science and technology.
Dumoulin-White stated, "It is humbling to be acknowledged by such a prestigious magazine as Popular Mechanics, a magazine, which portrayed technology that I was always awe struck with as a child. We believe our work with patented Theralase lasers and PDCs for the destruction of cancer cells is truly groundbreaking and I speak on behalf of the entire company to say we are very excited to receive this award. We plan to continue our work toward commercializing this technology for the real and tangible benefit of all."
Lothar Lilge, Ph.D., the principal investigator of the PDCs, a published expert on PDCs and a leading researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network stated, "We are currently awaiting the final approval to commence testing the PDCs in a live small animal model to evaluate toxicity. In vitro, the lead PDCs have demonstrated low reaction without the presence of light, proving the safety of the compounds and a moderate to high ability to destroy cancer cells when subjected to light, indicating their innate ability to destroy cancer cells. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid core tumours, such as: breast and prostate cancers. In conjunction with Virginia Tech, we will optimize the lead compounds for cancer cell destruction. Successful completion of a small animal pre clinical study and the knowledge accumulated from it in regards to PDC light dose interactions, such as toxicology, safety and efficacy, will pave the way for companion animal treatments and early human trials under FDA Phase 1, as early as 2011."
Popular Mechanics, published monthly by Hearst Magazines, inspires, instructs and influences almost 9 million curious readers. Their mindset-the desire to understand how the world works-drives them to explore, experiment with and experience a wide range of interests. The Award winners will be highlighted in the November issue of Popular Mechanics, on newsstands Oct. 12, with winner profiles currently online at www.popularmechanics.com/breakthrough10.
Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.
Theralase Technologies Inc. President and CEO, Roger Dumoulin-White joins Karen Brewer and Brenda Winkel of Virginia Tech to receive the award at the Hearst Tower in New York on October 5, 2010. Popular Mechanics Magazine's "Breakthrough Awards" is honouring the year's most impressive advances in science and technology.
Dumoulin-White stated, "It is humbling to be acknowledged by such a prestigious magazine as Popular Mechanics, a magazine, which portrayed technology that I was always awe struck with as a child. We believe our work with patented Theralase lasers and PDCs for the destruction of cancer cells is truly groundbreaking and I speak on behalf of the entire company to say we are very excited to receive this award. We plan to continue our work toward commercializing this technology for the real and tangible benefit of all."
Lothar Lilge, Ph.D., the principal investigator of the PDCs, a published expert on PDCs and a leading researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network stated, "We are currently awaiting the final approval to commence testing the PDCs in a live small animal model to evaluate toxicity. In vitro, the lead PDCs have demonstrated low reaction without the presence of light, proving the safety of the compounds and a moderate to high ability to destroy cancer cells when subjected to light, indicating their innate ability to destroy cancer cells. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid core tumours, such as: breast and prostate cancers. In conjunction with Virginia Tech, we will optimize the lead compounds for cancer cell destruction. Successful completion of a small animal pre clinical study and the knowledge accumulated from it in regards to PDC light dose interactions, such as toxicology, safety and efficacy, will pave the way for companion animal treatments and early human trials under FDA Phase 1, as early as 2011."
Popular Mechanics, published monthly by Hearst Magazines, inspires, instructs and influences almost 9 million curious readers. Their mindset-the desire to understand how the world works-drives them to explore, experiment with and experience a wide range of interests. The Award winners will be highlighted in the November issue of Popular Mechanics, on newsstands Oct. 12, with winner profiles currently online at www.popularmechanics.com/breakthrough10.
Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.
Subscribe to:
Posts (Atom)